

Audited Full Year Financial Statement And Dividend Announcement For The Year Ended 31 December 2011

PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR RESULTS

1(a) **An income statement and statement of comprehensive income, or a statement of comprehensive income, for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.**

Group	2011 S\$'000	2010 S\$'000	Change %
Revenue	272,783	239,123	14.1
Other operating income	2,180	3,474	(37.2)
Inventories and consumables used	(32,254)	(26,622)	21.2
Purchased and contracted services	(19,231)	(17,483)	10.0
Staff costs	(133,046)	(115,760)	14.9
Depreciation of property, plant and equipment	(7,240)	(6,935)	4.4
Operating lease expenses	(5,867)	(5,588)	5.0
Other operating expenses	(17,815)	(17,240)	3.3
Profit from operating activities	59,510	52,969	12.3
Finance income	182	366	(50.3)
Finance expenses	(252)	(239)	5.4
Profit before tax	59,440	53,096	11.9
Tax expense	(8,819)	(7,614)	15.8
Profit for the year	<u>50,621</u>	<u>45,482</u>	11.3
Attributable to :			
Owners of the Company	50,396	45,265	11.3
Non-controlling interests	225	217	3.7
Profit for the year	<u>50,621</u>	<u>45,482</u>	11.3

Excluding the fair value gain of investment properties and jobs credit grant, the Group's results showed a **15.9%** increase in profit after tax from **S\$41.8** million to **S\$48.4** million for the year ended 31 December 2011.

RafflesMedicalGroup

- 1(a) An income statement and statement of comprehensive income, or a statement of comprehensive income, for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year (Cont'd).

Consolidated statement of comprehensive income	2011 S\$'000	2010 S\$'000	Change %
Profit for the year	50,621	45,482	11.3
Other comprehensive income			
Foreign currency translation differences for foreign operations	(170)	374	nm
Total comprehensive income for the year	50,451	45,856	10.0
Attributable to:			
Owners of the Company	50,226	45,639	10.1
Non-controlling interests	225	217	3.7
Total comprehensive income for the year	50,451	45,856	10.0

Note: nm denotes not meaningful.

Explanatory notes to the income statement

- Staff costs increased in tandem with higher volume of business in the Group. The rate of increase for staff costs in 2011 is slightly higher than the growth in revenue due to the absence of jobs credit grant in 2011.
- Higher inventories and consumables used were due to increased sales of medical supplies and services.
- Profit from ordinary activities before taxation includes the following:

Group	2011 S\$'000	2010 S\$'000
(a) Other operating income		
Gain on disposal of property, plant and equipment	6	474
Change in fair value in investment properties	2,174	3,000
(b) Other operating expenses		
Allowance for doubtful receivables	1,038	1,194
Amortisation of intangible assets	-	51
Property, plant and equipment written off	155	31

- The adjustment for under and over-provision of tax in respect of prior years are as follows:

Group	2011 S\$'000	2010 S\$'000
Deferred tax expense		
Under provision in respect of prior years	-	22
Current tax expense		
(Over)/Under provision in respect of prior years	(91)	8

RafflesMedicalGroup

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

	Group		Company	
	2011 S\$'000	2010 S\$'000	2011 S\$'000	2010 S\$'000
Non-current assets				
Property, plant and equipment	141,896	144,253	3,242	3,252
Intangible assets	316	316	245	245
Investment properties	199,700	88,000	-	-
Subsidiaries	-	-	258,985	202,881
Deferred tax assets	-	895	-	-
	<u>341,912</u>	<u>233,464</u>	<u>262,472</u>	<u>206,378</u>
Current assets				
Inventories	5,136	5,083	1,356	1,258
Trade and other receivables	31,855	26,066	64,563	18,251
Cash and cash equivalents	49,691	107,137	28,860	88,664
	<u>86,682</u>	<u>138,286</u>	<u>94,779</u>	<u>108,173</u>
Total assets	<u>428,594</u>	<u>371,750</u>	<u>357,251</u>	<u>314,551</u>
Equity attributable to owners of the Company				
Share capital	190,344	177,006	190,344	177,006
Reserves	143,663	109,414	78,885	55,955
	<u>334,007</u>	<u>286,420</u>	<u>269,229</u>	<u>232,961</u>
Non-controlling interests	702	542	-	-
Total equity	<u>334,709</u>	<u>286,962</u>	<u>269,229</u>	<u>232,961</u>
Non-current liabilities				
Deferred tax liabilities	1,579	1,690	359	402
Interest-bearing liabilities	16,000	18,000	-	-
	<u>17,579</u>	<u>19,690</u>	<u>359</u>	<u>402</u>
Current liabilities				
Trade and other payables	59,765	50,972	82,364	76,905
Interest-bearing liabilities	5,451	4,577	3,451	2,577
Current tax payable	11,090	9,549	1,848	1,706
	<u>76,306</u>	<u>65,098</u>	<u>87,663</u>	<u>81,188</u>
Total liabilities	<u>93,885</u>	<u>84,788</u>	<u>88,022</u>	<u>81,590</u>
Total equity and liabilities	<u>428,594</u>	<u>371,750</u>	<u>357,251</u>	<u>314,551</u>

Explanatory notes to the Statement of Financial Position

1. The Group's net cash position decreased from S\$84.6 million as at 31 December 2010 to S\$28.2 million as at 31 December 2011. This was attributed mainly to the payments for the purchase of properties amounting to S\$109.5 million and cash dividends of S\$8.7 million offset by strong operating cash flows generated by the Group in line with the higher volume of business.
2. Investment properties increased mainly due to acquisition of units in Thong Sia Building and Samsung Hub.
3. Trade and other receivables increased in tandem with higher volume of business in the Group.
4. The increase in trade and other payables was mainly driven by higher business volume in the Group.

1(b)(ii) Aggregate amount of group's borrowings and debt securities.

Amount repayable in one year or less, or on demand

As at 31/12/2011		As at 31/12/2010	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
-	5,451	-	4,577

Amount repayable after one year

As at 31/12/2011		As at 31/12/2010	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
-	16,000	-	18,000

Details of any collateral

Nil.

RafflesMedicalGroup

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

	2011	2010
	S\$'000	S\$'000
Cash flows from operating activities		
Profit before tax	59,440	53,096
Adjustments for :-		
Amortisation of intangible assets	-	51
Depreciation of property, plant and equipment	7,240	6,935
Equity-settled share-based payment transactions	2,558	2,359
Finance expenses	252	239
Finance income	(182)	(366)
Gain on disposal of property, plant and equipment	(6)	(474)
Property, plant and equipment written off	155	31
Revaluation gain of investment properties	(2,174)	(3,000)
Operating profit before working capital changes	<u>67,283</u>	<u>58,871</u>
Changes in working capital :-		
Inventories	(53)	190
Trade and other receivables	(5,803)	(1,816)
Trade and other payables	8,534	(883)
Cash generated from operations	<u>69,961</u>	<u>56,362</u>
Taxes paid	(6,494)	(6,913)
Interest paid	(209)	(239)
Net cash from operating activities	<u>63,258</u>	<u>49,210</u>
Cash flows from investing activities		
Interest received	196	399
Proceeds from sale of property, plant and equipment	9	1,661
Purchase of investment properties	(109,526)	-
Purchase of property, plant and equipment	(5,017)	(5,452)
Net cash used in investing activities	<u>(114,338)</u>	<u>(3,392)</u>
Cash flows from financing activities		
Dividends paid to owners of the Company	(8,696)	(15,698)
Dividends paid to non-controlling shareholder of the subsidiary	(65)	(52)
Proceeds from issue of shares under share option scheme	3,499	4,347
Proceeds from bank loan	21,385	6,870
Repayment of bank loan	(22,527)	(8,220)
Net cash used in financing activities	<u>(6,404)</u>	<u>(12,753)</u>
Net (decrease)/increase in cash and cash equivalents	(57,484)	33,065
Cash and cash equivalents at 1 January	107,137	74,089
Effect of exchange rate changes on balances held in foreign currency	38	(17)
Cash and cash equivalents at 31 December	<u>49,691</u>	<u>107,137</u>
Cash and cash equivalents at end of the year comprise :		
Cash & fixed deposits	<u>49,691</u>	<u>107,137</u>

Explanatory note to the Statement of Cash Flows

The Group's cash and cash equivalents decreased from S\$107.1 million as at 31 December 2010 to S\$49.7 million as at 31 December 2011. This was attributed mainly to the payments for the purchase of properties amounting to S\$109.5 million and cash dividends of S\$8.7 million offset by strong operating cash flows generated by the Group in line with the higher volume of business.

RafflesMedicalGroup

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

Group	Share capital S\$'000	Currency translation reserve S\$'000	Share option reserve S\$'000	Accumulated profits S\$'000	Total attributable to owners of the Company S\$'000	Non-controlling interests S\$'000	Total equity S\$'000
At 1 January 2010	172,659	(321)	5,422	72,013	249,773	377	250,150
Comprehensive income for the year							
Profit for the year	-	-	-	45,265	45,265	217	45,482
Other comprehensive income							
Foreign currency translation differences for foreign operations	-	374	-	-	374	-	374
Total comprehensive income for the year	-	374	-	45,265	45,639	217	45,856
Transactions with owners, recorded directly in equity							
Contributions by and distributions to owners							
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	4,347	-	-	-	4,347	-	4,347
Value of employee services received for issue of share options	-	-	2,359	-	2,359	-	2,359
Final dividend paid of 2.0 cents per ordinary share - Cash	-	-	-	(10,452)	(10,452)	-	(10,452)
Interim dividend paid of 1.0 cent per ordinary share - Cash	-	-	-	(5,246)	(5,246)	-	(5,246)
Dividends distributed to non-controlling shareholder of a subsidiary	-	-	-	-	-	(52)	(52)
Total contributions by and distributions to owners	4,347	-	2,359	(15,698)	(8,992)	(52)	(9,044)
At 31 December 2010	177,006	53	7,781	101,580	286,420	542	286,962

RafflesMedicalGroup

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year (Cont'd).

Group	Share capital S\$'000	Currency translation reserve S\$'000	Share option reserve S\$'000	Accumulated profits S\$'000	Total attributable to owners of the Company S\$'000	Non-controlling interests S\$'000	Total equity S\$'000
At 1 January 2011	177,006	53	7,781	101,580	286,420	542	286,962
Comprehensive income for the year							
Profit for the year	-	-	-	50,396	50,396	225	50,621
Other comprehensive income							
Foreign currency translation differences for foreign operations	-	(170)	-	-	(170)	-	(170)
Total comprehensive income for the year	-	(170)	-	50,396	50,226	225	50,451
Transactions with owners, recorded directly in equity							
Contributions by and distributions to owners							
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	3,499	-	-	-	3,499	-	3,499
Value of employee services received for issue of share options	-	-	2,558	-	2,558	-	2,558
Issue of shares in lieu of cash dividends of 2.5 cents per ordinary share pursuant to Raffles Medical Group Ltd Scrip Dividend Scheme	9,839	-	-	-	9,839	-	9,839
Final dividend paid of 2.5 cents per ordinary share - Cash	-	-	-	(3,359)	(3,359)	-	(3,359)
Final dividend paid of 2.5 cents per ordinary share - Scrip	-	-	-	(9,839)	(9,839)	-	(9,839)
Interim dividend paid of 1.0 cent per ordinary share - Cash	-	-	-	(5,337)	(5,337)	-	(5,337)
Dividends distributed to non-controlling interests of a subsidiary	-	-	-	-	-	(65)	(65)
Total contributions by and distributions to owners	13,338	-	2,558	(18,535)	(2,639)	(65)	(2,704)
At 31 December 2011	190,344	(117)	10,339	133,441	334,007	702	334,709

RafflesMedicalGroup

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year (Cont'd).

Company	Share capital S\$'000	Share option reserve S\$'000	Accumulated profits S\$'000	Total S\$'000
At 1 January 2010	172,659	5,422	32,642	210,723
Comprehensive income for the year				
Profit for the year	-	-	31,230	31,230
Total comprehensive income for the year	-	-	31,230	31,230
Transactions with owners, recorded directly in equity				
Contributions by and distributions to owners				
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	4,347	-	-	4,347
Value of employee services received for issue of share options	-	2,359	-	2,359
Final dividend paid of 2.0 cents per ordinary share - Cash	-	-	(10,452)	(10,452)
Interim dividend paid of 1.0 cent per ordinary share - Cash	-	-	(5,246)	(5,246)
Total contributions by and distributions to owners	4,347	2,359	(15,698)	(8,992)
At 31 December 2010	177,006	7,781	48,174	232,961
At 1 January 2011	177,006	7,781	48,174	232,961
Comprehensive income for the year				
Profit for the year	-	-	38,907	38,907
Total comprehensive income for the year	-	-	38,907	38,907
Transactions with owners, recorded directly in equity				
Contributions by and distributions to owners				
Issue of shares upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	3,499	-	-	3,499
Value of employee services received for issue of share options	-	2,558	-	2,558
Issue of shares in lieu of cash dividends of 2.5 cents per ordinary share pursuant to Raffles Medical Group Ltd Scrip Dividend Scheme	9,839	-	-	9,839
Final dividend paid of 2.5 cents per ordinary share - Cash	-	-	(3,359)	(3,359)
Final dividend paid of 2.5 cents per ordinary share - Scrip	-	-	(9,839)	(9,839)
Interim dividend paid of 1.0 cent per ordinary share - Cash	-	-	(5,337)	(5,337)
Total contributions by and distributions to owners	13,338	2,558	(18,535)	(2,639)
At 31 December 2011	190,344	10,339	68,546	269,229

RafflesMedicalGroup

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles, as well as the number of shares held as treasury shares, if any, against the total number of issued shares excluding treasury shares of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

During the year ended 31 December 2011, the Company issued 4,753,258 new shares due to the allotment and issue of ordinary shares arising from the application of Raffles Medical Group Scrip Dividend Scheme in respect of the final dividend for the financial year ended 31 December 2010, as well as the allotment and issue of 3,636,000 new ordinary shares pursuant to the exercise by option holders under the Raffles Medical Group (2000) Share Option Scheme.

Exercise price per share	S\$0.185	S\$0.23	S\$0.32	S\$0.33	S\$0.42	S\$0.68
Number of new shares issued	69,000	125,000	238,000	46,000	135,000	300,000

Exercise price per share	S\$0.71	S\$0.78	S\$1.14	S\$1.15	S\$1.24	S\$1.66
Number of new shares issued	251,000	1,043,000	50,000	233,000	271,000	875,000

On 1 April 2011, options to subscribe for 5,000,000 ordinary shares at an exercise price of S\$2.20 were granted to 410 eligible participants pursuant to the Raffles Medical Group (2010) Share Option Scheme.

As at 31 December 2011, there were outstanding options for conversion into 20,111,000 (2010 : 19,894,000) ordinary shares.

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at end of the immediately preceding year.

	31/12/2011	31/12/2010
Number of issued shares excluding treasury shares	534,333,651	525,944,393

1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

There were no sales, transfers, disposal, cancellation and/or use of treasury shares as at 31 December 2011 (31 December 2010 : Nil).

2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.

The financial statements on consolidated results for the year ended 31 December 2011 have been audited in accordance with Singapore Standards on Auditing.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter).

As per attached.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

The accounting policies and methods of computations applied by the Group are consistent with those used in its audited financial statements as at 31 December 2010, except for those as disclosed under item 5 below.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

From 1 January 2011, the Group has applied the Amendments to the revised FRS 24 *Related Party Disclosures* (2010). Changes to the Group's accounting policies have been made as required, in accordance with the transitional provisions in the respective FRS.

The adoption of FRS 24 (2010) affects only disclosures made in the financial statements. There is no financial effect on the results and financial position of the Group for the current and previous financial years. Accordingly, the adoption of FRS 24 (2010) has no impact on earnings per share.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

	2011	2010
Earnings per ordinary share for the period based on 1(a) above :-		
(i) Basic earnings per share [A]	9.50 cents	8.65 cents
(ii) Diluted earnings per share [B]	9.36 cents	8.51 cents

[A] The calculation of earnings per ordinary share was based on weighted average number of shares of 530,300,257 (2010 : 523,267,127) in issue during the year.

[B] The calculation of earnings per ordinary share (on a fully diluted basis) was based on weighted average number of shares of 538,191,490 (2010 : 531,752,618) in issue during the year.

7. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:-

- (a) current financial period reported on; and
(b) immediately preceding financial year.

	Group		Company	
	31/12/2011	31/12/2010	31/12/2011	31/12/2010
Net asset value per ordinary share [C]	62.51 cents	54.46 cents	50.39 cents	44.29 cents

[C] The calculation of net asset value per ordinary share was based on 534,333,651 shares as at 31 December 2011 (31 December 2010 : 525,944,393).

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:-

- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**
- (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

The Group's revenue for the full year 2011 reached a record high of **S\$272.8** million, an increase of **14.1%** as compared to **S\$239.1** million in 2010. The healthy growth of **14.1%** was attributed to positive contributions in all divisions of the Group. Revenue from Hospital and Healthcare Services divisions increased by **14.6%** and **10.9%** respectively.

Improved operating efficiencies, higher patient load and patient acuity, the recruitment of more specialist consultants and a wider range of medical specialties contributed to the improved profit from operating activities which grew from **S\$53.0** million in 2010 to **S\$59.5** million in 2011, an increase of **12.3%**.

The Group's net profit after tax grew **11.3%** to **S\$50.6** million from **S\$45.5** million over last year in line with better operating performance. Excluding the impact of jobs credit grant received by the Group in 2010 and the fair value gain of investment properties, the Group's results showed a **15.9%** increase in profit after tax from **S\$41.8** million to **S\$48.4** million for the year ended 31 December 2011.

The Group had a healthy cash position of **S\$50.0** million as at 31 December 2011, from the continued strong cash operating cashflows generated by the Group after distributing cash dividends of **S\$8.7** million. The strong cash position will enable the Group to fund its growth.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

The current financial year's results are in line with the Directors' expectations as disclosed in the Group's Q3 2011 results announcement.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

With improving economic data in the US and renewed efforts in the Eurozone to resolve its sovereign debt crisis, the Group is cautiously optimistic that global economic condition is gradually improving. Notwithstanding continued uncertainties in the global economic environment, the Group expects to benefit from the strong demand for high quality healthcare services locally and from the region, driven by rising affluence and an aging population.

RafflesHospital continues to demonstrate good growth in its operations as it focuses on quality and value-driven curative healthcare services. **RafflesHospital** is expected to perform well and would contribute positively to the Group's performance as it continues to actively market and diversify its foreign patient base, recruiting more specialists, increasing its breadth of specialist staff and strengthen its competencies.

In line with this, **RafflesHospital** is focused on expanding its premises at the North Bridge Road hospital. Whilst the Raffles Hospital had received its grant of provisional permission from the Urban Redevelopment Authority for the additional 102,408 square feet expansion, it is working with the team of consultants to finalise plans and to ensure minimum disruptions to existing facilities and patient services during the construction of the Hospital extension. When completed, the additional area will enable the Group to increase its clinical services and specialist offerings.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months (Cont'd)

The Group has also appointed consultants to work on the 42,668 square feet property at 30 Bideford Road to retrofit it to house the Group's specialist centre operations. The Group expects to commence clinical operations in the Orchard Road shopping precinct in the first half of 2013.

Leveraging on its comprehensive range of wellness and primary care services, **RafflesMedical** provides one-stop healthcare solutions for both individuals and organisations. **RafflesMedical** continues to open new branches in 2011. New clinics at Changi City Point and Asia Square will cater to the business community while that at I12 Katong (former Katong Mall) will provide medical care to the residential population in Katong and Marine Parade. **RafflesMedical** also expects to benefit from the higher demand for primary care services, driven locally by recent government initiatives to expand the "Community Health Assist Scheme – CHAS".

With additional beds of new public and private hospitals coming onstream over the next few years, the healthcare landscape will continue to remain competitive. Whilst adding the Specialist Medical Centre in Orchard Road and expanding **RafflesHospital**, the Group continues to be vigilant and responsive to new opportunities that may appear on the horizon.

Barring unforeseen circumstances, the Directors are optimistic that the Group will continue to grow in 2012.

11. Dividend

(a) Current Financial Period Reported On

Any dividend declared for the current financial period reported on? Yes

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in cents)	1.0 cent per ordinary share (one tier tax)
Tax Rate	Tax Exempt

Name of Dividend	Final
Dividend Type	Ordinary
Dividend Amount per Share (in cents)	3.0 cents per ordinary share (one tier tax)
Tax Rate	Tax Exempt

11. Dividend

(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year? Yes

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in cents)	1.0 cent per ordinary share (one tier tax)
Tax Rate	Tax Exempt

Name of Dividend	Final
Dividend Type	Ordinary
Dividend Amount per Share (in cents)	2.5 cents per ordinary share (one tier tax)
Tax Rate	Tax Exempt

(c) Date payable

The Directors are pleased to recommend a final dividend of 3.0 cents per share amounting approximately to S\$16.03 million in respect of the financial year ended 31 December 2011 for approval by the shareholders at the next Annual General Meeting to be convened on 27 April 2012. Including the interim net dividend of 1 cent per share paid in September 2011, the total dividends for the financial year ended 31 December 2011 would amount to 4.0 cents per share, an increase of 0.5 cent (14.3%) as compared to financial year ended 31 December 2010.

The date of payment of the proposed dividends, if approved at the Annual General Meeting, will be announced at a later date.

(d) Books closure date

The books closure date will be announced at a later date.

(e) Scrip dividend scheme

The Scrip Dividend Scheme will be applicable to the final dividend. The issue price of a new share shall not be set at more than 10% discount to, nor shall it exceed the average of the last dealt prices of a share on the SGX-ST for each of the market days during the price determination period (being the period commencing on the day on which the shares are first quoted ex-dividend and ending on the books closure date to determine the entitlements to the final dividend). Further details will be announced at a later date.

12. If no dividend has been declared/recommended, a statement to that effect.

Not applicable.

13. If the Group has obtained a general mandate from shareholders for Interested Parties Transactions (IPTs), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Company did not obtain a general mandate from shareholders for IPTs.

PART II - ADDITIONAL INFORMATION REQUIRED FOR FULL YEAR ANNOUNCEMENT
(This part is not applicable to Q1, Q2, Q3 or Half Year Results)

14. Segmented revenue and results for business or geographical segments (of the group) in the form presented in the issuer's most recently audited annual financial statements, with comparative information for the immediately preceding year

14.(a) Business Segments

	Healthcare services S\$'000	Hospital services S\$'000	Investment holdings S\$'000	Total S\$'000
2011				
Revenue and expenses				
External revenue	105,163	177,167	10,472	292,802
Inter-segment revenue	1,990	9,939	8,090	20,019
Finance expenses	(25)	-	(227)	(252)
Depreciation of property, plant and equipment	(1,725)	(3,085)	(158)	(4,968)
Reportable segment profit before tax	9,677	42,888	9,147	61,712
Reportable segment assets	318,706	93,325	457,479	869,510
Capital expenditure	2,079	2,938	109,526	114,543
Reportable segment liabilities	104,639	42,537	301,591	448,767
2010				
Revenue and expenses				
External revenue	94,864	154,575	7,940	257,379
Inter-segment revenue	1,357	9,088	7,811	18,256
Finance expenses	(31)	-	(208)	(239)
Depreciation of property, plant and equipment	(1,701)	(2,797)	(165)	(4,663)
Amortisation of intangible assets	-	-	(51)	(51)
Reportable segment profit before tax	8,257	38,502	8,609	55,368
Reportable segment assets	322,103	88,964	346,379	757,446
Capital expenditure	1,410	4,042	-	5,452
Reportable segment liabilities	97,038	43,081	196,740	336,859

RafflesMedicalGroup

14.(a) Business Segments (cont'd)

Reconciliations of reportable segment revenues, profit or loss, assets and liabilities and other material items

	2011 S\$'000	2010 S\$'000
Revenues		
Total revenue for reportable segments	292,802	257,379
Elimination of inter-segment revenue	(20,019)	(18,256)
Consolidated revenue	<u>272,783</u>	<u>239,123</u>
Profit or loss		
Total profit for reportable segments	61,712	55,368
Adjustment for depreciation of property, plant and equipment	(2,272)	(2,272)
Consolidated profit before tax	<u>59,440</u>	<u>53,096</u>
Assets		
Total assets for reportable segments	869,510	757,446
Elimination of inter-segment assets	(440,916)	(386,591)
Unallocated amounts – deferred tax assets	-	895
Consolidated total assets	<u>428,594</u>	<u>371,750</u>
Liabilities		
Total liabilities for reportable segments	448,767	336,859
Elimination of inter-segment liabilities	(367,551)	(263,310)
Unallocated amounts – current and deferred tax liabilities	12,669	11,239
Consolidated total liabilities	<u>93,885</u>	<u>84,788</u>

Other material items

	Reportable segment totals S\$'000	Adjustment S\$'000	Consolidated totals S\$'000
2011			
Depreciation of property, plant and equipment	4,968	2,272	<u>7,240</u>
2010			
Depreciation of property, plant and equipment	4,663	2,272	<u>6,935</u>

The hospital building at North Bridge Road is owned by a subsidiary and classified as Investment Property in the subsidiary's standalone financial statements. In accordance with the Group's accounting policies, investment property is measured at fair value and not depreciated.

For the preparation of the consolidated financial statements, the hospital building is reclassified from Investment Property to Property, Plant and Equipment as the building is used in the supply of hospital services by the Group. Accordingly, the carrying value of the hospital building is depreciated over its useful life in the consolidated financial statements of the Group.

The amount of \$2,272,000 (2010: \$2,272,000) relates to the depreciation of the hospital building for the year ended 31 December 2011.

15. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments.

Please refer to Item 8.

16. A breakdown of sales.

		Group		
		2011 S\$'000	2010 S\$'000	Change %
16(a)	Revenue reported for first half year	131,396	114,772	14.5
16(b)	Operating profit after tax before deducting non-controlling interests reported for second half year	22,245	19,724	12.8
16(c)	Revenue reported for second half year	141,387	124,351	13.7
16(d)	Operating profit after tax before deducting non-controlling interests reported for second half year	28,376	25,758	10.2

17. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year.

	2011 S\$'000	2010 S\$'000
Ordinary	18,535	15,698
Preference	-	-
Total	18,535	15,698

18. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13). If there are no such persons, the issuer must make an appropriate negative statement.

The Board of Directors hereby confirm that none of the personnel occupying managerial positions in the Company or any of its principal subsidiaries is a relative of a director, chief executive officer or substantial shareholder of the Company.

BY ORDER OF THE BOARD

Tay Kim Choon Kimmy
Company Secretary
20 February 2012